Evercore ISI Cuts Baxter International (NYSE:BAX) Price Target to $23.00

Baxter International (NYSE:BAX) had its price target decreased by stock analysts at Evercore ISI from $24.00 to $23.00 in a report released on Monday,MarketScreener reports. Evercore ISI’s price objective would indicate a potential upside of 14.26% from the company’s current price.

A number of other equities analysts have also recently issued reports on the stock. Jefferies Financial Group cut their target price on shares of Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, October 8th. Wells Fargo & Company reduced their price objective on Baxter International from $21.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Stifel Nicolaus reduced their price target on Baxter International from $25.00 to $22.00 in a research report on Friday, October 31st. Finally, The Goldman Sachs Group cut their target price on Baxter International from $25.00 to $22.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $21.90.

Baxter International Stock Up 3.2%

Shares of BAX opened at $20.13 on Monday. Baxter International has a fifty-two week low of $17.40 and a fifty-two week high of $37.74. The company’s fifty day moving average is $18.83 and its two-hundred day moving average is $23.02. The firm has a market cap of $10.35 billion, a PE ratio of -30.49, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. The company has a quick ratio of 1.18, a current ratio of 1.84 and a debt-to-equity ratio of 1.21.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a positive return on equity of 17.38% and a negative net margin of 3.09%.The firm had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same quarter last year, the firm earned $0.80 EPS. Baxter International’s quarterly revenue was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. Analysts forecast that Baxter International will post 2.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BAX. Creative Financial Designs Inc. ADV lifted its holdings in shares of Baxter International by 169.6% during the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 619 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Baxter International by 14.4% during the third quarter. EverSource Wealth Advisors LLC now owns 5,448 shares of the medical instruments supplier’s stock worth $124,000 after acquiring an additional 686 shares during the period. Anchor Investment Management LLC raised its stake in Baxter International by 3.4% in the 1st quarter. Anchor Investment Management LLC now owns 21,164 shares of the medical instruments supplier’s stock worth $724,000 after purchasing an additional 701 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Baxter International by 40.1% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 2,831 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 810 shares during the period. Finally, CoreFirst Bank & Trust bought a new stake in Baxter International in the 2nd quarter valued at about $27,000. 90.19% of the stock is owned by institutional investors.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.